CCR2 and metabolic dysfunction-associated steatohepatitis: Targeting central pathways driving fibrosis progression, such as CCR2/CCR5-mediated accumulation of fibrogenic macrophages in the liver, might provide therapeutic opportunities for the therapy of NAFLD/NASH.